Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | RRM1 | P23921 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24804157 | 1.00 | DPP7 (0.48) | DPP7EPHX1USP2TSHRMMP8 | |
| SCHEMBL24804155 | 1.00 | DPP7 (0.48) | DPP7EPHX1USP2TSHRMMP8 | |
| SCHEMBL5021621 | 0.94 | DPP7 (0.56) | DPP7EPHX1MMP8RRM1 | |
| SCHEMBL14341512 | 0.92 | EPHX1 (0.57) | DPP7EPHX1MMP8RRM1 | |
| SCHEMBL5021622 | 0.92 | EPHX1 (0.57) | DPP7EPHX1MMP8RRM1 | |
| SCHEMBL13924949 | 0.92 | EPHX1 (0.57) | DPP7EPHX1MMP8RRM1 | |
| SCHEMBL15856115 | 0.92 | EPHX1 (0.57) | DPP7EPHX1MMP8RRM1 | |
| SCHEMBL17853878 | 0.91 | USP2 (0.50) | DPP7EPHX1USP2TSHRMMP8 | |
| SCHEMBL17527573 | 0.89 | ALDH1A2 (0.52) | DPP7EPHX1USP2TSHRMMP8 | |
| SCHEMBL5021623 | 0.86 | TSHR (0.50) | DPP7EPHX1USP2TSHRMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338415-A1 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE | GLYSCEND, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11795334-B2 | Photo-curable ink composition and method for forming image | FUJIFILM CORPORATION (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20230288623-A1 | OPTICAL FILM, OPTICAL LAMINATE, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230265346-A1 | LIQUID CRYSTAL COMPOSITION, OPTICALLY ANISOTROPIC LAYER, LAMINATE, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230213823-A1 | LIGHT ABSORPTION ANISOTROPIC FILM, LAMINATE, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230202146-A1 | LAMINATE AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230159827-A1 | LIQUID CRYSTAL COMPOSITION, FLUORINE-CONTAINING POLYMER, OPTICALLY ANISOTROPIC LAYER, LAMINATE, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-05-25 | — | — | US | disclosed |
| EP-3553147-B1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | TOKYO OHKA KOGYO CO LTD (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| EP-3792320-A1 | POLYMER COATINGS | Illumina, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-7935131-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | REXAHN PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-7857407-B2 | Image forming apparatus | FUJIFILM CORPORATION (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100080893-A1 | METHOD OF FORMING METAL FILM | FUJIFILM CORPORATION (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20080177303-A1 | Shape memory polymers | ROCHESTER, UNIVERSITY OF | 2008-07-24 | — | — | US | disclosed |
| US-20080176085-A1 | HYDROPHILIC COMPOSITION AND HYDROPHILIC MEMBER | FUJIFILM CORPORATION (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080075873-A1 | thermally-decomposing polymer blends including an alkoxide compound; catalyst promotes the reaction of polymer and alkoxides; heating to decompose the polymer to hydrophilic; soiling resistance, fogging resistance and abrasion resistance; protective coatings for mirrors, cars, lenses | FUJIFILM CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20070046715-A1 | Image forming apparatus | FUJI PHOTO FILM CO., LTD. | 2007-03-01 | — | — | US | disclosed |
| US-5827863-A | Pyrazole derivatives as angiotensin II antagonists | J. URIACH & CIA, S.A. (ES) | 1998-10-27 | — | — | US | disclosed |
| US-5224987-A | Aqueous carriers with colors and tertiary amide penetrants | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | APEH, LNPEP, CPA3 | DPP7 788/4885EPHX1 2351/4885USP2 789/4885 |
| US-20230338415-A1 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE | SLC10A2, PYGL, SLC10A1 | DPP7 388/4885EPHX1 4203/4885USP2 3337/4885 |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | DPP7 697/4885EPHX1 3244/4885USP2 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.